BioMarin Pharmaceutical Inc.
US ˙ NasdaqGS ˙ US09061G1013

SecurityBMRN / BioMarin Pharmaceutical Inc.
InstitutionTri-continental Corp
Latest Disclosed Ownership21,253 shares
Latest Disclosed Value $ 1,168,277
Tri-continental Corp reports 1.11% decrease in ownership of BMRN / BioMarin Pharmaceutical Inc.

On August 22, 2025 - Tri-continental Corp filed a NPORT-P form disclosing ownership of 21,253 shares of BioMarin Pharmaceutical Inc. (US:BMRN) valued at $1,168,277 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 27, 2025 disclosing 21,491 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of -1.11% during the quarter. The current value of the position is $1,161,689 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-22 2025-06-30 NP BioMarin Pharmaceutical EC US09061G1013 21,253 -238 -1.11 1,168 -23.11 0.0627
2025-05-27 2025-03-31 NP BioMarin Pharmaceutical EC US09061G1013 21,491 -455 -2.07 1,519 5.34 0.0850
2025-02-28 2024-12-31 NP BioMarin Pharmaceutical EC US09061G1013 21,946 -1,316 -5.66 1,443 -11.80 0.0774
2024-11-25 2024-09-30 NP BioMarin Pharmaceutical EC US09061G1013 23,262 -408 -1.72 1,635 -16.07 0.0853
2024-08-27 2024-06-30 NP BioMarin Pharmaceutical EC US09061G1013 23,670 -1,010 -4.09 1,949 -9.61 0.1070
2024-05-28 2024-03-31 NP BioMarin Pharmaceutical EC US09061G1013 24,680 -458 -1.82 2,156 -11.06 0.1183
2024-02-26 2023-12-31 NP BioMarin Pharmaceutical EC US09061G1013 25,138 -516 -2.01 2,424 6.79 0.1416
2023-11-27 2023-09-30 NP BioMarin Pharmaceutical EC US09061G1013 25,654 -538 -2.05 2,270 -0.04 0.1414
2023-08-24 2023-06-30 NP BioMarin Pharmaceutical EC US09061G1013 26,192 -479 -1.80 2,270 -12.46 0.1365
2023-05-25 2023-03-31 NP BioMarin Pharmaceutical EC US09061G1013 26,671 -633 -2.32 2,593 -8.21 0.1598
2023-02-24 2022-12-31 NP BioMarin Pharmaceutical EC US09061G1013 27,304 -538 -1.93 2,826 19.70 0.1791
2022-11-25 2022-09-30 NP BioMarin Pharmaceutical EC US09061G1013 27,842 -248 -0.88 2,360 1.42 0.1557
2022-08-24 2022-06-30 NP BioMarin Pharmaceutical EC US09061G1013 28,090 -620 -2.16 2,328 5.15 0.1438
2022-05-25 2022-03-31 NP BioMarin Pharmaceutical EC US09061G1013 28,710 -362 -1.25 2,214 -13.82 0.1155
2022-02-24 2021-12-31 NP BioMarin Pharmaceutical EC US09061G1013 29,072 -2,284 -7.28 2,569 5.98 0.1280
2021-11-23 2021-09-30 NP BioMarin Pharmaceutical EC US09061G1013 31,356 -644 -2.01 2,424 -9.25 0.1246
2021-08-25 2021-06-30 NP BioMarin Pharmaceutical EC US09061G1013 32,000 0 0.00 2,670 10.51 0.1356
2021-05-25 2021-03-31 NP BioMarin Pharmaceutical EC US09061G1013 32,000 -600 -1.84 2,416 -15.47 0.1288
2021-02-24 2020-12-31 NP BioMarin Pharmaceutical EC US09061G1013 32,600 -1,400 -4.12 2,859 10.52 0.1638
2020-11-24 2020-09-30 NP BioMarin Pharmaceutical EC US09061G1013 34,000 -600 -1.73 2,587 -39.40 0.1637
2020-08-26 2020-06-30 NP BioMarin Pharmaceutical EC US09061G1013 34,600 -200 -0.57 4,268 45.14 0.2827
2020-05-28 2020-03-31 NP BioMarin Pharmaceutical EC US09061G1013 34,800 0 0.00 2,941 -0.07 0.2274
2020-02-25 2019-12-31 NP BioMarin Pharmaceutical EC 09061G101 34,800 -1,400 -3.87 2,942 20.62 0.1767
2019-11-26 2019-09-30 NP BioMarin Pharmaceutical EC US09061G1013 36,200 36,200 2,440 0.1538
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.